Abstract
A recently released white paper calls for updating FDA regulations around the development of cell therapies. The authors suggest changing the investigational new drug pathway exploratory trials, including easing manufacturing requirements for early studies and allowing for greater flexibility to revise protocols as studies progress.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
September 2019
Volume 9, Issue 9
Volume 9, Issue 9
Call Made to Speed Cell-Therapy Development
Jump to section
Advertisement